KEISHA HINDS: Open Payments
NPI 1750784419 · BRANDYWINE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$3,451 in 109 payments from 38 companies in 2025. Trend: 2023 $3,126 · 2024 $3,035 · 2025 $3,451
Food & beverage: $2,369Long term medical supply or device loan: $1,082
| Company | Payments | Amount |
|---|---|---|
| Novartis Pharmaceuticals Corporation | 22 | $1,298 |
| Merck Sharp & Dohme LLC | 9 | $205 |
| AstraZeneca Pharmaceuticals LP | 6 | $178 |
| BeOne Medicines USA, Inc. | 5 | $145 |
| PFIZER INC. | 6 | $134 |
| Janssen Biotech, Inc. | 5 | $121 |
| Genentech USA, Inc. | 4 | $102 |
| PharmaEssentia USA Corporation | 3 | $98 |
| Incyte Corporation | 4 | $85 |
| Stemline Therapeutics Inc. | 3 | $83 |
Products named: KISQALI, KEYTRUDA, BESREMI, Venclexta, BRUKINSA, Orserdu, CABOMETYX, Enhertu.
Industry payments across MD — which companies pay providers there.
